admin

TopGum Industries Ltd. announced the signing of a binding Letter of Intent (LOI) to acquire U.S.-based manufacturing operations, marking its strategic entry into the pharmaceutical sector. The development, announced on March 6, 2026, reflects the company’s expansion beyond nutraceuticals into regulated pharmaceutical dosage forms.   Entry into Pharmaceutical Dosage Forms The acquisition enables TopGum to […]

Scinai Immunotherapeutics Ltd. announced the completion of its acquisition of Recipharm Israel Ltd., marking a strategic expansion into Active Pharmaceutical Ingredient (API) development and manufacturing. The development, announced on April 10, 2026, also includes a commercial collaboration with Recipharm to strengthen end-to-end drug development capabilities.   Expanding API Development and Manufacturing The acquired facility is

Scinai Immunotherapeutics Ltd. highlighted its expanded contract development and manufacturing (CDMO) platform and immunology pipeline during BIO-Europe Spring 2026. The update, shared on March 18, 2026, reflects the company’s strategic focus on integrating early-stage development capabilities with advanced manufacturing services, including Active Pharmaceutical Ingredients (API).   Expanding API Development Capabilities As part of its CDMO

RPG Life Sciences Limited outlined its long-term growth strategy, which includes expanding its presence in the Active Pharmaceutical Ingredient (API) segment through potential acquisitions. The development highlights the company’s intent to strengthen its API manufacturing capabilities alongside its broader pharmaceutical expansion plans . Strategic Focus on API Capacity Expansion As part of its roadmap toward

Recipharm announced the divestment of its API development and manufacturing facility in Israel to Scinai Immunotherapeutics Ltd., as part of its ongoing strategic transformation. The development, announced on February 16, 2026, reflects the company’s focus on optimizing its global manufacturing network and prioritizing core business segments.   Divestment of API Manufacturing Facility The divested facility,

The global pharmaceutical industry is witnessing a surge in strategic partnerships and acquisitions as companies strengthen their pipelines and invest in next-generation therapeutics. According to a roundup published on February 25, 2026, major deals involving Novo Nordisk and GSK highlight growing focus on biologics, drug delivery innovation, and cardiopulmonary treatments.   Novo Nordisk Partners with

Orchid Pharma Limited announced plans to strengthen its Active Pharmaceutical Ingredient (API) manufacturing capabilities through capacity expansion and new product initiatives, supporting its targeted revenue growth.   Expanding API Manufacturing Capacity The company has commissioned a new API manufacturing plant in Chennai, aimed at increasing its overall production capacity by approximately 25%. This expansion is

India’s pharmaceutical manufacturing landscape is witnessing a significant capacity expansion as Neuland Laboratories announced plans to establish a new commercial-scale peptide manufacturing facility at its Bonthapally campus in Hyderabad. The development, announced on March 9, 2026, reflects growing global demand for complex peptide-based therapeutics and reinforces India’s role in advanced API manufacturing.   The new

The global pharmaceutical industry continues to rely heavily on small molecule Active Pharmaceutical Ingredients (APIs), which account for a significant share of approved drugs worldwide. According to insights published on February 10, 2026, leading small molecule API manufacturers are playing a critical role in supporting drug development, commercialization, and global supply chains.   Dominance of

The high-potency active pharmaceutical ingredient (HPAPI) segment is rapidly transforming the global pharmaceutical manufacturing landscape, driven by increasing demand for targeted therapies and complex drug formulations. According to insights published on January 15, 2026 by Recipharm, several critical trends are shaping HPAPI manufacturing in 2026, reflecting a shift toward advanced technologies, enhanced safety, and sustainable